Ibrutinib

Generic Name
Ibrutinib
Brand Names
Imbruvica
Drug Type
Small Molecule
Chemical Formula
C25H24N6O2
CAS Number
936563-96-1
Unique Ingredient Identifier
1X70OSD4VX
Background

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...

Indication

Ibrutinib is indicated for the treatment of the following conditions.

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Waldenström's macroglobulinemia

Chronic graft-versus-host disease (cGVHD)

Mantle cell lymphoma (MCL)

Marginal zone lymphoma (MZL)

Associated Conditions
Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
Associated Therapies
-
Clinical Trials
Related News

Ublituximab + Ibrutinib in Select B-cell Malignancies

First Posted Date
2013-12-17
Last Posted Date
2022-10-24
Lead Sponsor
TG Therapeutics, Inc.
Target Recruit Count
66
Registration Number
NCT02013128
Locations
🇺🇸

TG Therapeutics Investigational Trial Site, Vancouver, Washington, United States

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

First Posted Date
2013-12-10
Last Posted Date
2024-12-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
66
Registration Number
NCT02007044
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Phase 2
Completed
Conditions
B-cell Lymphoma
Marginal Zone Lymphoma
Interventions
Drug: ibrutinib
First Posted Date
2013-11-11
Last Posted Date
2019-10-16
Lead Sponsor
Pharmacyclics LLC.
Target Recruit Count
63
Registration Number
NCT01980628
Locations
🇬🇧

Site Reference ID/Investigator# 030, Manchester, England, United Kingdom

🇧🇪

Site Reference ID/Investigator# 560, Ghent, Oost-vlaanderen, Belgium

🇬🇧

Site Reference ID/Investigator# 814, Oxford, England, United Kingdom

and more 22 locations

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

First Posted Date
2013-11-11
Last Posted Date
2019-04-16
Lead Sponsor
Pharmacyclics LLC.
Target Recruit Count
80
Registration Number
NCT01980654
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 9 locations

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

First Posted Date
2013-10-31
Last Posted Date
2018-07-24
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
160
Registration Number
NCT01973387

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

First Posted Date
2013-10-14
Last Posted Date
2021-12-21
Lead Sponsor
Pharmacyclics LLC.
Target Recruit Count
84
Registration Number
NCT01962792
Locations
🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

University of California Los Angeles, Los Angeles, California, United States

and more 14 locations

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

First Posted Date
2013-10-07
Last Posted Date
2024-10-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
34
Registration Number
NCT01955499
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇨🇦

University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

First Posted Date
2013-06-26
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
547
Registration Number
NCT01886872
Locations
🇺🇸

Wayne Hospital, Greenville, Ohio, United States

🇺🇸

Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States

🇺🇸

Diagnostic and Treatment Center, Weston, Wisconsin, United States

and more 942 locations

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

First Posted Date
2013-06-26
Last Posted Date
2022-09-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
27
Registration Number
NCT01886859
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

🇺🇸

Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

First Posted Date
2013-06-19
Last Posted Date
2024-12-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
113
Registration Number
NCT01880567
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy